GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website
June 13 2023 - 7:35AM
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a
biotechnology company advancing an innovative pipeline of Natural
Killer T (“NKT”) cell modulators for the treatment of inflammatory,
fibrotic and autoimmune diseases, today announced its new corporate
branding and launch of its new corporate website, gribio.com.
“As we continue to evolve as a company, expand
our awareness and reach in the public investment markets and
advance our clinical development programs, we believed it was an
important step to align our corporate branding identity and website
with the vision we have for GRI Bio. We remain committed to
advancing our leading NKT platform technology, which we believe
holds an opportunity for all stakeholders as well as the potential
for significant value creation. Over the course of the past several
months, we have made encouraging progress on all fronts and are
laser focused on successfully executing a number of value-driving
milestones. We are excited to take this next step in the evolution
of our Company and position ourselves to unlock further potential,”
commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio.
Please click on the following link for a video
message from Dr. Hertz discussing the Company’s rebranding:
https://gribio.com/video613
The Company is currently advancing its lead
development program GRI-0621, a type 1 invariant NKT (iNKT)
antagonist, as a once-daily oral capsule for the treatment of
idiopathic pulmonary fibrosis (IPF) with the potential to expand
into additional fibrotic indications. In multiple disease models
and preliminary data from trials to date1improvement in fibrosis,
liver function tests (LFTs), and other markers of inflammation and
injury in patients were observed. GRI Bio plans to leverage the
505(b)(2) regulatory pathway to launch a Phase 2a biomarker study
evaluating GRI-0621 for the treatment of IPF, expected to commence
in the second half of 2023.
The Company’s second lead asset, GRI-0803, is a
novel activator of human type 2 NKT cells currently in development
for the treatment of autoimmune disorders, with an initial focus on
systemic lupus erythematosus (SLE). Additionally, with a library of
over 500 proprietary compounds, GRI has the potential to fuel a
growing pipeline. The Company has ongoing evaluations for pipeline
expansion opportunities targeting potential indications in multiple
sclerosis, inflammatory bowel disease, and additional autoimmune
indications.
For more information about the Company’s
clinical development programs and ongoing pre-clinical and clinical
trials, visit gribio.com and connect with the Company on Twitter
and LinkedIn.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical
company focused on fundamentally changing the way inflammatory,
fibrotic and autoimmune diseases are treated. GRI Bio’s therapies
are designed to target the activity of NKT cells, which are key
regulators earlier in the inflammatory cascade, to interrupt
disease progression and restore the immune system to homeostasis.
NKT cells are innate-like T cells that share properties of both NK
and T cells and are a functional link between the innate and
adaptive immune responses. Type 1 invariant NKT (iNKT) cells play a
critical role in propagating the injury, inflammatory response, and
fibrosis observed in inflammatory and fibrotic indications. GRI
Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity
and is being developed as a novel oral therapeutic for the
treatment of idiopathic pulmonary fibrosis, a serious disease with
significant unmet need. The Company is also developing a pipeline
of novel type 2 NKT agonists for the treatment of systemic lupus
erythematosus. Additionally, with a library of over 500 proprietary
compounds, GRI Bio has the ability to fuel a growing pipeline.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words
such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
“will,” “would,” or the negative of these words or other similar
expressions. These forward-looking statements are based on the
Company’s current beliefs and expectations. Forward-looking
statements include, but are not limited to, statements regarding:
the Company’s expectations with respect to development and
commercialization of the Company’s product candidates, the
initiation or completion of clinical trials, the potential benefits
and impact of the Company’s product candidates and the related
timing of regulatory approvals, if any, evaluations and judgements
regarding the Company’s intellectual property position, the ability
of the Company to achieve the milestones presented and the timing
of such milestones and any implication that the results or
preliminary results of earlier or prior clinical trials will be
representative or indicative of future clinical trials,. Actual
results may differ from the forward-looking statements expressed by
the Company in this press release and consequently, you should not
rely on these forward-looking statements as predictions of future
events. These forward-looking statements are subject to inherent
uncertainties, risks and assumptions that are difficult to predict,
including, without limitation: (1) the inability to maintain the
listing of the Company’s common stock on Nasdaq; (2) changes in
applicable laws or regulations; (3) the inability of the Company to
raise financing in the future; (4) the success, cost and timing of
the Company’s product development activities; (5) the inability of
the Company to obtain and maintain regulatory clearance or approval
for their products, and any related restrictions and limitations of
any cleared or approved product; (6) the inability of the Company
to identify, in-license or acquire additional technology; (7) the
inability of the Company to compete with other companies currently
marketing or engaged in the development of products and services
that the Company is currently developing; (8) the size and growth
potential of the markets for the Company’s products and services,
and its ability to serve those markets, either alone or in
partnership with others; (9) inaccuracy in the Company’s estimates
regarding expenses, future revenue, capital requirements and needs
for and the ability to obtain additional financing; (10) the
Company’s ability to protect and enforce its intellectual property
portfolio; and (10) other risks and uncertainties indicated from
time to time in the Company’s filings with the U.S. Securities and
Exchange Commission (the “SEC”), including the risks and
uncertainties described in the “Risk Factors” section of the
Company’s most recent Annual Report on Form 10-K filed with the SEC
on February 24, 2023 and Quarterly Report on Form 10-Q filed with
the SEC on May 15, 2023 and subsequently filed reports.
Forward-looking statements contained in this announcement are made
as of this date, and the Company undertakes no duty to update such
information except as required under applicable law.
Investor Contact:JTC Team,
LLCJenene Thomas(833) 475-8247GRI@jtcir.com
1 I. Maricic et al., Differential
Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role
in Progression of Nonalcoholic Steatohepatitis. J
Immunol 201, 3017-3035 (2018), Tazoral™ for
the Treatment of Moderate to Very Severe Plaque Psoriasis Briefing
Document, Allergan
(https://wayback.archive-it.org/7993/20170405104812/https://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4062B1_01_Allergan-Background.pdf)
GRI Bio (NASDAQ:GRI)
Historical Stock Chart
From Apr 2024 to May 2024
GRI Bio (NASDAQ:GRI)
Historical Stock Chart
From May 2023 to May 2024